JIP
SKYE icon

Jaffetilchin Investment Partners’s Skye Bioscience SKYE Stock Holding History

Jaffetilchin Investment Partners’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2
Closed -$8 – 1349
2024
Q3 		$8 Buy
+2
New +$11 ﹤0.01% 1352

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Jaffetilchin Investment Partners's SKYE Position: Q4 2024 in Review

Jaffetilchin Investment Partners sold out of Skye Bioscience (SKYE) in Q4 2024, closing a stake of 2 shares — an estimated $8 sold.

Jaffetilchin Investment Partners first reported a position in SKYE in Q3 2024 and held it in 1 quarter. The position peaked at $8 in Q3 2024. 73 funds tracked by Wall St. Rank hold SKYE as of Q4 2024.

  • Jaffetilchin Investment Partners reported no remaining Skye Bioscience position as of Q4 2024 after selling out during the quarter.
  • Jaffetilchin Investment Partners sold 2 Skye Bioscience shares in Q4 2024, an estimated $8.
  • Jaffetilchin Investment Partners first reported a position in Skye Bioscience in Q3 2024 and held it in 1 quarter.
  • Jaffetilchin Investment Partners's Skye Bioscience position peaked at $8 in Q3 2024.
  • 73 funds tracked by Wall St. Rank held Skye Bioscience as of Q4 2024.

Based on Jaffetilchin Investment Partners's 13F filing for Q4 2024, filed 13 Feb 2025.